The Pharmacy Times® Respiratory Syncytial Virus Resource Center is a comprehensive source for clinical news and expert insights on treating and preventing respiratory syncytial virus.
April 30th 2024
Prevention of acute cardiac events may be another consideration for future postlicensure studies of RSV vaccines.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA Approves First Respiratory Syncytial Virus Vaccine for Adults Aged 60 Years and Older
May 3rd 2023Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Read More
Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine
March 30th 2023The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.
Read More
FDA Accepts Biologics License Application for RSV Maternal Vaccine Candidate
February 23rd 2023If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.
Read More